56 y/o F with NF1, sarcoma s/p resection, DVT in lower extremity was on xarelto now with clot extension. She is on oxcarbazepine so might be the reason why she “fail AC”. Are other DOAc such as Padraxa less likely to be affected/less interactions with oxcarb (must have for her)?
Yes both dabigatran and edoxaban would not interact with Oxcarbazapine as neither rely on CYP3A4 for metabolism. If you consider this cancer associated VTE we typically prefer edoxaban since there is more data in this patient population but if not, either agent could be utilized.
